NCT03089229 is a Phase 1, PHASE2 clinical trial of HAT01H Cream in Atopic Dermatitis, sponsored by Haus Bioceuticals.

Who is sponsoring NCT03089229?

NCT03089229 is sponsored by Haus Bioceuticals.

What drugs are being tested in NCT03089229?

Interventions in NCT03089229: HAT01H Cream, Vehicle Cream.

What condition does NCT03089229 study?

NCT03089229 studies Atopic Dermatitis, Eczema.

Is NCT03089229 still recruiting?

NCT03089229 is currently completed. Last updated 7 November 2018.

Last reviewed 2018-11-07 · How we verify

NCT03089229

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis

Completed Phase 1, PHASE2 Last updated 7 November 2018

What this trial tests

Phase 1, PHASE2 trial testing HAT01H Cream in Atopic Dermatitis in 30 participants. Completed in 31 July 2017.

Timeline

26 March 2017

Primary endpoint
30 June 2017

31 July 2017

Quick facts

Lead sponsor	Haus Bioceuticals
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	30
Start date	26 March 2017
Primary completion	30 June 2017
Estimated completion	31 July 2017
Sites	1 location across India

Drugs / interventions tested

HAT01H Cream — full drug profile →
Vehicle Cream — full drug profile →

Conditions studied

Atopic Dermatitis — all drugs for Atopic Dermatitis →
Eczema — all drugs for Eczema →

Sponsor

Haus Bioceuticals — full company profile →

Who can join

Adults 12 to 65, any sex, with Atopic Dermatitis or Eczema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by a disturbance of epidermal-barrier function that results in intensely pruritic subacute and chronic eczematous plaques. The current therapy of AD is reactive, where the flares are treated through symptomatic management with topical corticosteroids and calcineurin inhibitors. Given that these medications have long-term side-effects, and given the chronically relapsing immunopathogenic nature of AD, there is an imperative need for safer anti-inflammatory medications. Haus Bioceuticals (Haus) has developed a novel topical treatment for eczema/atopic dermatitis (AD) denoted HAT01H, and have demonstrated that HAT01H is safe and profoundly effective in the treatment of AD, controlling signs and symptoms in 85% of patients with AD. This study is aimed to further test the efficacy and safety of topical HAT01H in patients with moderate to severe atopic dermatitis.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

New and Upcoming Topical Treatments for Atopic Dermatitis: A Review of the Literature.
Sideris N, Paschou E, Bakirtzi K, Kiritsi D, et al · · 2022 · cited 28× · PMID 36078904 · DOI 10.3390/jcm11174974
Topical anti-inflammatory treatments for eczema: network meta-analysis.
Lax SJ, Van Vogt E, Candy B, Steele L, et al · · 2024 · cited 22× · PMID 39105474 · DOI 10.1002/14651858.cd015064.pub2

Verify or expand the search:

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting

Other Haus Bioceuticals trials

Trials by the same sponsor.

NCT03406117 — A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests · Phase 4 · completed
NCT03848806 — Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis · Phase 2 · completed
NCT03059693 — Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis · Phase 1, PHASE2 · completed
NCT03069144 — Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03089229 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Haus Bioceuticals
Last refreshed: 7 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03089229.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing